Hasan Şenol Coşkun

Hasan Şenol Coşkun

Auto-generated profile, based on publicly available information

Hasan Şenol Coşkun

Akdeniz University

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2020 in European Journal of Breast Health
Verified
Journal Article
Closed access
FAFatma Arikan
Fatma Arikan
OKOznur Korukcu
Oznur Korukcu
AKAysegul Kucukcakal
Aysegul Kucukcakal
HCHasan Senol Coskun
Hasan Senol Coskun
Breast cancer,body image,chemotherapy,self-efficacy,sexual adjustment

30 November 2014 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
HBHakan Bozcuk
Hakan Bozcuk
MYMustafa Yıldız
Mustafa Yıldız
MAMehmet Artac
Mehmet Artac
MKMurat KOÇER
Murat KOÇER
ÇKÇ. Kaya
Ç. Kaya
BSB. Savas
B. Savas

19 November 2014 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
SGsema sezgin goksu
sema sezgin goksu
SGSeyda Gunduz
Seyda Gunduz
DODilek Unal Ozakca
Dilek Unal Ozakca
MUMukremin Uysal
Mukremin Uysal
DADeniz Arslan
Deniz Arslan
HCHasan S Coskun
Hasan S Coskun
An increasing number of patients receive palliative chemotherapy near the end of life. The aim of this study is to evaluate the aggressiveness of chemotherapy in Turkish individuals near the end of life. Patients diagnosed with solid tumors and died from 2010 to 2011 in the medical oncology department of Akdeniz University were included in the study. Data about the diagnosis, treatment details and imaging procedures were collected. Three hundred and seventy-three people with stage IV solid tumors died from 2010 to 2011 in our clinic. Eighty-nine patients (23.9%) patients underwent chemotherapy in the last month of life while 39 patients (10.5%) received chemotherapy in the last 14 days. The probability of undergoing chemotherapy in the last month of life was influenced by: age, ‘newly diagnosed’ patients, and performance status. There was no significant association of chemotherapy in the last month of life with gender and tumor type. Having a PET-CT scan did not alter the chemotherapy decision. In conclusion, chemotherapy used in the last month of life in a tertiary care center of Turkey is high. Increasing quality of life should be a priority near the end of life and physicians should consider ceasing chemotherapy and direct the patient to early palliative care.

30 March 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SYSuayib Yalcin
Suayib Yalcin
FDFaysal Dane
Faysal Dane
BOBerna Oksuzoglu
Berna Oksuzoglu
NONuriye Yildirim Ozdemir
Nuriye Yildirim Ozdemir
AIAbdurrahman Işıkdoğan
Abdurrahman Işıkdoğan
SKSaadettin Kilickap
Saadettin Kilickap
Background: Combination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in advanced pancreatic adenocarcinoma is unknown. Methods: A total of 125 patients were randomized to combination therapy (1000 mg/m2 gemcitabine + 125 mg/m2 nab-paclitaxel) and single-agent gemcitabine (1000 mg/m2) arms to take treatment weekly for 7 of 8 weeks, and following 3 of 4 weeks, until progression or severe toxicity. Primary endpoints were three-months of definitive deterioration free percent of patients, and QoL. Results: Overall QoL analyses showed that 34 and 58.3% of cases in gemcitabine and gemcitabine+nab-P arms had no deterioration in 3rd month QoL scores (p = 0.018). These proportions were 27.3 and 36.6% in 6th month assessments, respectively (p = 0.357). Median overall survivals in combination and single-agent arms were 9.92 months and 5.95 months, respectively (HR: 0.64, 95% CI: 0.42–0.86, p = 0.038). Median progression free survivals in these treatment arms were 6.28 and 3.22 months, respectively (HR: 0.58, 95% CI: 0.39–0.87, p = 0.008). Median time-to-deterioration were 5.36 vs 3.68 months, and objective response rates were 37.1% vs 23.7% (p = 0.009), respectively in combination and single-agent arms. Conclusions: Combination therapy with gemcitabine + nab-paclitaxel had better overall and progression-free survival than gemcitabine alone. Also, combination therapy showed increased response rate without toxicity or deteriorated QoL. Combination treatment with gemcitabine and nab-paclitaxel may provide significant benefit for advanced pancreatic cancer. Trial registration: This study has been registered in ClinicalTrials.gov as NCT03807999 on January 8, 2019 (retrospectively registered).

11 March 2022 in Japan Journal of Nursing Science
Verified
Journal Article
Closed access
MAMüge Altınışık
Müge Altınışık
BKBurcu Kocabıyık
Burcu Kocabıyık
FAFatma Arıkan
Fatma Arıkan
HŞHuri Yeşim Şevik
Huri Yeşim Şevik
HCHasan Şenol Coşkun
Hasan Şenol Coşkun

30 August 2020 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
AAAli Alkan
Ali Alkan
AYArzu Yaşar
Arzu Yaşar
ZGZeynep Gülsüm Güç
Zeynep Gülsüm Güç
MGMustafa Gürbüz
Mustafa Gürbüz
TBTuğba Başoğlu
Tuğba Başoğlu
FŞFiliz Çay Şenler
Filiz Çay Şenler